Christos Vaklavas, MD, discussed barriers limiting rural oncology access and challenges to adopting resource-intensive therapies.
Commentary|Articles|March 27, 2026
CDC Opioid Guidelines at 10: Impact, Misuse, and Lessons: Michael Lynch, MD
Author(s)Sabrina McCrear, Michael Lynch, MD
Fact checked by: Maggie L. Shaw
A decade after the CDC opioid guidelines, Michael Lynch, MD, examines misapplication, fentanyl’s role, and evolving pain management strategies.
Advertisement
Advertisement
The CDC’s Clinical Practice Guidelines for Prescribing Opioids for Pain are
Related to this article
Trial, transplant equity gaps in AML; Texas Medicaid funding dispute; pediatric GLP-1 access gaps; earlier biologic use; eye care restores vision.
Patient factors and access barriers are reshaping treatment sequencing and individualized care for relapsed multiple myeloma, Amandeep Godara, MBBS, said.
FDA cut required monitoring for tarlatamab’s first 2 doses from 22-24 hours to 6-8 hours, easing a barrier to community cancer care.
Shiven B. Patel, MD, MBA, shares strategies for closing biomarker testing gaps, including among patients with non–small cell lung cancer.
Community oncology leaders urge 340B overhaul so drug discounts follow vulnerable cancer patients, with audits, transparency, and tighter contract-pharmacy rules. This commentary will be featured on the Cover of the October issue of Evidence-Based Oncology.
Reference countries have limited room to simply raise their own drug budgets to absorb the pressure, the lead study author explains.
New Harris Poll data show mental health, access, and postpartum care gaps persist for US mothers, with Black and Hispanic women hit hardest.
Advertisement
Advertisement